Credit Suisse Maintains Underperform on Clover Health Investments, Lowers Price Target to $1.25
Credit Suisse Maintains Underperform on Clover Health Investments, Lowers Price Target to $1.25
瑞信在三葉草健康投資方面保持表現不足，將目標價格降至 1.25 美元
Credit Suisse analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Underperform and lowers the price target from $2.5 to $1.25.
瑞信分析師喬納森·永保持三葉草健康投資 (NASDAQ: CLOV) 與表現不佳和降低價格目標從 $2.5 至 $1.25.
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。